搜索
EyePoint Pharmaceuticals Inc
EYPT添加自选
12.190USD
-0.280-2.25%
收盘 07-24 16:00（美东）报价延迟15分钟
1.01B总市值
亏损市盈率 TTM
关于 EyePoint Pharmaceuticals Inc 公司
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc简介
公司代码EYPT
公司名称EyePoint Pharmaceuticals Inc
上市日期Jan 27, 2005
CEODuker (Jay S)
员工数量165
证券类型Ordinary Share
年结日Jan 27
公司地址480 Pleasant Street, Suite C400
城市WATERTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02472
电话16179265000
网址https://eyepointpharma.com/
公司代码EYPT
上市日期Jan 27, 2005
CEODuker (Jay S)
EyePoint Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
--
常见问题
EyePoint Pharmaceuticals Inc的前五大股东是谁？
EyePoint Pharmaceuticals Inc 的前五大股东如下：Dr. Jay S. Duker, M.D.
有多少机构持有EyePoint Pharmaceuticals Inc(EYPT)的股份？
截至2026Q1，共有381家机构持有EyePoint Pharmaceuticals Inc的股份，合计持有的股份价值约为88.53M，占公司总股份的105.59%。与2025Q4相比，机构持股有所增加，增幅为-2754490.00。
哪个业务部门对EyePoint Pharmaceuticals Inc的收入贡献最大？
在2026Q1，YUTIQ业务部门对EyePoint Pharmaceuticals Inc的收入贡献最大，创收1.60M，占总收入的5.10%。